comprehensive -WSS

comprehensive

author：entertainment 2025-10-02 10:48:25 - browse：233

Sage Therapeutics, a biotech developing an experimental treatment for postpartum depression, this week trumpeted strong results from a clinical trial, which cheered investors and pushed up its stock price. But outside the lab, the company’s aggressive efforts to raise awareness of postpartum depression have proved divisive.

The campaign’s message: “When it comes to postpartum depression, silence sucks.” It features close-up photos of distressed, tearful women who can’t speak — because they have pacifiers stuck in their mouths.

The images have been plastered on bus stops, buses, conference booths, and on a dedicated website. The ads don’t specifically mention Sage’s drug, which still needs further testing before the company can bring it to the Food and Drug Administration for possible approval. Instead, they urge women to talk “openly and honestly” about postpartum depression. An estimated 600,000 women in the U.S. alone experience symptoms, which range from insomnia and irritability to difficulty bonding with their baby.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Novavax promises a turnaround & Lilly roils the obesity market
Next article： How I ended up pumping milk in a bathroom stall at JPM 2024

focus

WSS

Idaho abortion case may prompt more restrictions in other states

Doudna institute plans to 'cure hundreds of diseases' with CRISPR

Medicare Advantage enrollment grows 7.1% to 33.4 million people

Doudna institute plans to 'cure hundreds of diseases' with CRISPR

Obamacare plans could cover weight loss drugs

A new drug could help frostbite victims avoid its ravages

knowledge

comprehensive

Wikipedia

Alkermes shareholders re

Idaho abortion case may prompt more restrictions in other states

The high cost of giving birth even with insurance

How I ended up pumping milk in a bathroom stall at JPM 2024

ChatGPT in medicine: STAT answers readers' burning questions

Ukraine seeks to reclaim its role as a hub for clinical trials

Wildfire smoke exposes gaps in outdoor worker protections

HHS names first

Cancer drug shortages should be causing more outrage

Hospitals are piloting generative AI tools as regulators play catch

hotspot

A new drug could help frostbite victims avoid its ravages

JPM 2024: FogPharma’s CEO unveils ‘contrarian’ plan in oncology

Abridge raises $150m as clinical notes automation market heats up

Readout LOUD podcast: 2023 in review, and a look at biotech in 2024

Bipartisan group of lawmakers warns of a rising Chinese threat to U.S. biotech

How I ended up pumping milk in a bathroom stall at JPM 2024

focus

hotspot

focus

leisure time